Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancerПодробнее

DESTINY-Breast04: T-DXd for patients with HER2-low mBCПодробнее

DESTINY-Breast04: practice-changing results for HER2-low breast cancerПодробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBCПодробнее

Understanding CA 15-3 - Marker for Breast Cancer Monitoring I Dr Kaushal Yadav Onco Surgeon GurugramПодробнее

HER2-Low Breast Cancer: DESTINY or Good Science?Подробнее

The exciting new field of HER2-low breast cancerПодробнее

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancerПодробнее

2nd line treatment options for HR+ breast cancer.Подробнее

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patientsПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее

Novel treatment options for HER2-low breast cancerПодробнее

DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancerПодробнее

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in ReviewПодробнее

Latest news in HER2-low breast cancerПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

HER2-low expression in breast cancerПодробнее

Reflections on the DESTINY-Breast04 trial | Patricia LoRussoПодробнее